COVID-19 vaccination-associated myelitis
Open Access
- 31 March 2021
- journal article
- editorial
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 114 (8), 591-593
- https://doi.org/10.1093/qjmed/hcab069
Abstract
Of all COVID-19 vaccination-associated adverse events, 2.69% may be neurological in nature. We report the first case of myelitis from India with ChAdOX1 nCoV-19 vaccine; the patient had excellent recovery. Having occurred after an administration of > 50 million doses, benefits of vaccination seem to outweigh the risk of adverse events.Keywords
This publication has 6 references indexed in Scilit:
- ANA Investigates: Neurological Complications of COVID‐19 VaccinesAnnals of Neurology, 2021
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKThe Lancet, 2020
- Covid-19: Oxford researchers halt vaccine trial while adverse reaction is investigatedPublished by BMJ ,2020
- Covid-19: What do we know about “long covid”?BMJ, 2020
- Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): Case definitions and guidelines for collection, analysis, and presentation of immunization safety dataVaccine, 2007
- Proposed diagnostic criteria and nosology of acute transverse myelitisNeurology, 2002